76 completed, 18 terminated, 5 recruiting, 4 withdrawn. 45 Phase 3, 32 Phase 1, 17 Phase 2, 4 Phase 4, 2 Not applicable.
Follow Grünenthal GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of GRT7040 in Adults With Acute Pain Following Bunionectomy GRT7040, Hydrocodone bitartrate/ acetaminophen (HB/APAP), Placebo (matched to HB/APAP) - Acute Pain, Bunionectomy | Phase 2 | Not yet recruiting | Grünenthal GmbH | 400 | 2026-09-01 | 2026-09-15 |
| Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]GRT6019 [14C]GRT6019 - Healthy Male Volunteers | Phase 1 | Completed | Grünenthal GmbH | 10 | 2026-03-25 | 2026-08-12 |
| A First-in-human Trial of GRT7041 in Healthy Participants GRT7041 SAD, Placebo, Midazolam - Treatment of Pain | Phase 1 | Recruiting | Grünenthal GmbH | 70 | 2026-01-14 | 2026-02-20 |
| A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male Participants GRT6019 - Duchenne Muscular Dystrophy (DMD) | Phase 1 | Completed | Grünenthal GmbH | 24 | 2026-01-06 | 2026-08-12 |
| A Trial to Investigate Safety and Pharmacokinetics of GRT6019, Including Food Effect, in Healthy Male Participants GRT6019 - Duchenne Muscular Dystrophy (DMD) | Phase 1 | Completed | Grünenthal GmbH | 18 | 2025-11-21 | 2026-02-13 |
| Capsaicin in Digital Osteoarthritis Versus Control Capsaicin 179 Mg Cutaneous Patch, Capsaicine low dose 0.04 % - Osteoarthritis Hand, Neuropathic Pain | Phase 4 | Recruiting | University Hospital, Clermont-Ferrand | 120 | 2025-03-07 | 2025-03-13 |
| Chemotherapy Induced Peripheral Neuropathy by Taxanes and Capsaicin 8%. Capsaicin 8% Patch, antidepressants (tricyclics and serotonin reuptake inhibitor SRIs), antiepiletics, lidocaine patches, and neurostimulation - Patients With Taxane-induced Chronic Neuropathic Pain | Not applicable | Recruiting | Hospital Ambroise Paré Paris | 50 | 2024-03-12 | 2026-05-22 |
| Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy Capsaicin, Duloxetine - Chemotherapy-induced Peripheral Neuropathy | Phase 3 | Recruiting | Institut Cancerologie de l'Ouest | 274 | 2023-10-20 | 2026-03-31 |
| Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee RTX-GRT7039, Placebo - Osteoarthritis | Phase 3 | Completed | Grünenthal GmbH | 466 | 2022-09-26 | 2026-03-18 |
| Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee RTX-GRT7039 - Osteoarthritis | Phase 3 | Completed | Grünenthal GmbH | 714 | 2022-09-15 | 2026-03-12 |
| Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis RTX-GRT7039, Placebo - Osteoarthritis | Phase 3 | Completed | Grünenthal GmbH | 469 | 2022-08-26 | 2026-03-18 |
| Biometric and Biological Data for Diagnosis and Therapy of Pain Patients Small Fiber Neuropathy | Unknown | RWTH Aachen University | 68 | 2020-10-10 | 2023-01-09 | |
| Preferences in Pain Treatment: A Discrete Choice Experiment in Patients With Peripheral Neuropathic Pain (pNP) Discrete Choice Experiment - Neuralgia Peripheral, Neuropathic Pain | Completed | LinkCare GmbH | 153 | 2020-02-11 | 2021-02-21 | |
| TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection, Placebo 4 mL Solution for Injection, MRI - Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Recruiting | University Hospital, Strasbourg, France | 40 | 2019-10-29 | 2025-06-29 |
| Bioequivalence of Two Fixed-dose Combination Tablets Containing Estradiol and Nomegestrol Acetate Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Reference Product), Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Test Product) - Bioequivalence | Phase 1 | Withdrawn | Grünenthal GmbH | 2019-10-01 | 2019-07-15 | |
| Providing Standardized Consented PROMs (Patient Reported Outcome Measures) for Improving Pain Treatment Prospective data collection - Pain, Postoperative | Completed | Prof. Dr. Winfried Meissner | 3322 | 2019-09-24 | 2025-04-01 | |
| Translational Research in Pelvic Pain Endometriosis, Bladder Pain Syndrome | Completed | University of Oxford | 787 | 2019-09-01 | 2023-04-04 | |
| taPentadol cLinical prAcTice IN belgiUM Severe Pain Syndromes | Completed | Dafne Balemans | 55 | 2019-07-29 | 2022-02-09 | |
| A Study to Investigate Differences in the Extent and Rate of Absorption of Doxylamine/Pyridoxine From 2 Different Products Under Fasting Conditions doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination, Diclegis (Registered Trademark) - Bioavailability | Phase 1 | Withdrawn | Grünenthal GmbH | 2019-06-01 | 2019-07-11 | |
| Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery Capsaicin, Pregabalin - Breast Cancer Patient | Phase 3 | Completed | Institut Cancerologie de l'Ouest | 140 | 2019-03-19 | 2026-05-05 |
Showing 20 of 105. Sign in to see all of them.
Pain (32) · Acute Pain (17) · Chronic Pain (16) · Pain, Postoperative (14) · Neuralgia (12) · Osteoarthritis (12) · Low Back Pain (10) · Agnosia (9) · Arthralgia (6) · Back Pain (5) · Diabetic Neuropathies (4) · Neoplasms (4) · Osteoarthritis, Knee (4) · Bunion (3) · Complex Regional Pain Syndromes (3)
Tapentadol (31) · 6-amino-1-hydroxyhexane-1,1-diphosphonate (4) · Buprenorphine (4) · Capsaicin (4) · Lidocaine (4) · Transdermal Patch (4) · Acetaminophen (3) · Hydrocodone (3) · Morphine (3) · Oxycodone (3) · Pregabalin (3) · Tramadol (3) · Analgesics, Opioid (2) · Diclofenac (2) · Drug Evaluation (2)
Germany (31) · United States (28) · France (21) · United Kingdom (18) · Poland (16) · Spain (16) · Canada (10) · Belgium (8) · Hungary (7) · Italy (7) · Austria (6) · Mexico (6) · Netherlands (6) · Bulgaria (5) · Czechia (5)
Wolfgang Timmer, Dr. (3) · Ralf Baron, Prof. Dr. (2) · Ad A.M. Masclee, MD, PhD (1) · Alain Serrie, Dr. (1) · Barbara Hoggart, Dr. MD (1) · Dominique Fletcher, Prof. (1)
PMID 23340531, PMID 24985410, PMID 23709304, PMID 24353047, PMID 24916058, PMID 19203298, PMID 19301937, PMID 19301989, PMID 19366301, PMID 19432499, PMID 19445652, PMID 19480610, PMID 19485723, PMID 20119464, PMID 20602712, PMID 21162697, PMID 21494892, PMID 22059194, PMID 22443293, PMID 22769236, PMID 22792000, PMID 23475406, PMID 23703422, PMID 24353022, PMID 24738609, PMID 24750558, PMID 25054392, PMID 25985806, PMID 26095455, PMID 26293513, PMID 26428249, PMID 27062079, PMID 30614286, PMID 31213888, PMID 32600454, PMID 32664901, PMID 38016907, PMID 38414426, PMID 40050054, PMID 41065659, PMID 41690858, PMID 41705870
2009 (6), 2016 (3), 2014 (2), 2017 (1)